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Portal diversion In glycogen storage 
disease 
On Octobcc 15, 1963, an UvI-yeac~ld 
girl with glycogen storage disease was treated 
at the University of Colorado by perform-
ance of a portacaval transposition.8 The ob-
jectives of the operation were to make die-
tary glucose more readily available to the 
peripheral tissues by means of the portal 
diversion, to deglycogenate the swollen liver, 
and to spare the patient the possible hazards 
of Eck fistula by restoring a portal inflow 
with systemic blood from the suprarenal in-
ferior vena cava. The physiologic basis for 
the undertaking had been laid by extensive 
investigations in dogs. 7 ,8 The original re-
port of this case speculated that the same 
result might have been obtained with a 
simple portacaval shunt, omitting the po-
tentially hazardous anastomosis of the in-
ferior vena cava to the central portal vein. 
The enzyme deficiency in the first patient 
was of hepatic amylo-1,6-glucosidase, thereby 
classifying the glycogen storage disorder as 
Type IIIB.3 One and a half years later, a 
7-year-old boy underwent the same opera-
tion, performed by Riddell, Davies, and 
Clark6 in Bristol, England, this time for the 
indication of an hepatic glucose-6-phospha-
tase deficiency (Type I). Their patient had 
a stormy postoperative course, with pro-
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found metabolic acidosis and acute ascites 
formation, but he ultimately, recovered. The 
same amelioration of symptoms, as well as 
rapid body growth, that was seen in the 
original patient was observed in this one. 
The child was in good condition when last 
seen in December, 1967, just before his 
family's immigration to Canada terminated 
the possibility of further examinations at the 
Bristol clinic.5 
A third attempt at portal diversion for the 
treatment of glycogen storage disease has 
been reported from the Cleveland Clinic 
by Hermann and Mercer, l again with en-
couraging results. However, there was an 
important deviation from the technique 
used in the earlier cases inasmuch as no at-
tempt was made to restore portal venous in-
flow. The patient has not suffered any 
apparent adverse long-term effects from the 
Eck fistula. 
The foregoing experience has suggested 
that cautious further exploration of portal 
diversion for the treatment of glycogen 
storage disease can be justified. This pos-
sibility will be supported in the present re-
port by a 5 year follow-up of the first patient 
so treated. In addition, a more recent at-
tempt at portacaval transposition which led 
to death will be described. In the last case, 
inability of the glycogen-laden liver to trans-
mit an augmented portal venous inflow from 
the inferior vena cava was the cause of fail-
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ure. As a consequence, it may be wise in 
future trials to consider performing only a 
portacaval shunt, as was done by Hermann 
and Mercer.1 
CASE REPORTS 
Case No. 1. The portacaval transposition was 
performed almost exactly 5 years ago and was 
reported with a 15 month follow-up.8 At operation 
the child had been found to have extensive venous 
collaterals in the abdominal wall, indicating the 
presence of portal hypertension. The procedure 
was well tolerated, and she was discharged from 
the hospital 9 days later. A venocavagram 3 
months postoperatively showed the portacaval 
anastomosis to be patent, although a large amount 
of the vena caval blood passed through paraverte-
bral collaterals. 
The child weighed 65 pounds prior to trans-
position and was 49 inches tall. Eleven months 
later she had gained 10 pounds in weight and 
4~ inches in height. On the Harvard growth 
chart, the jump in height represented a change 
from the tenth to the fiftieth percentile. By June, 
1967, 4 months posttransposition, her height had 
increased to 61 inches, and she weighed 11S~ 
pounds. At present she is 6301 inches tall and 
weighs 122 pounds. Her height and weight posi-
tions on the growth chart are now at the 55 and 
80 percentile levels. 
Biopsies were obtained of the child's liver a few 
weeks before and 9 and 43 months after porta-
caval transposition; the opportunity for the last 
open biopsy was provided by the need to perform 
splenectomy for the treatment of hypersplenism. 
The tissues were analyzed for glycogen and enzyme 
Table I. Enzymatic activities of homogenates 
prepared from liver biopsies of the first pa-
tient treated with portacaval transposition 
October, 
Enzyme 1963 June, 1967 
Glucose-6-phos- 1.9 2.2 
phatase (2.0-5.3)t 
Amyol-1, 6-glu- 0 0 0 
cosidase (0.04-0.18) 
Phosphorylase 17.4 10.3 7.5 
(16-33 ) 
Glycogen con- 10.1% 9.7% 9.5% 
tent 
* Activities in micromoles substrate utilized per minute per 
gram tissue. 
tThe figures in parentheses are the normal range. 
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concentrations at Washington University, St. 
Louis. The results are shown in Table I. Except 
for a progressive fall in phosphorylase activity, 
there were no significant changes in any of the 
measures in the several years between study of the 
first and last tissue specimens. 
It should be emphasized that these biochemical 
determinations were of concentration rather than 
content, a distinction of special importance in dis-
cussing total hepatic glycogen. The accelerated 
growth postoperatively has already been described. 
Serial hepatic scans during this time showed that 
the liver remained of fixed size. Thus, it might be 
said that after operation the child grew up around 
the enlarged organ to the extent that its relative, 
although not its abs.olute, size was decreased. 
Case No.2. A portacaval transposition was per-
formed on a 7-year-old boy on June 26, 1968. 
The preoperative diagnosis was glycogen storage 
disease, Type I. This impression was confirmed by 
the demonstration of absent glucose-6-phosphatase 
deficiency in the liver biopsy and a glycogen con-
centration of 9.4 percent; phosphorylase activity 
was essentially normal. The child had had 3 sib-
lings of whom only one was normal. The other 
2 had died, one a few days after birth and the 
other after almost 4 years. 
The patient was exceedingly small in stature, 
with a height of 36 inches and a weight of 32.3 
pounds; both values were at less than the 3 per-
centile level on the Harvard growth chart. The 
bone age, judged with a skeletal x-ray survey, was 
less than 3 years. There was massive hepatomegaly. 
Despite the small size of the patient and the 
marked liver enlargement, the portacaval trans-
position with the use of the previously described 
techniqueS was quite easy. There was no evidence 
whatever of increased venous collaterals. The 
portal pressure was not measured, but it was not 
thought to be elevated. The operating time was 3 
hours, and the blood loss was 100 ml. The only 
disquieting note during the procedure was the 
observation that the liver consistency became per-
ceptively firmer after the vena caval flow had 
been released into the liver. 
Within a few hours postopertively it became 
evident that a serious complication was evolving. 
Hypotension developed, as well as a metabolic 
acidosis more profound and refractory to treatment 
than any other ever seen by the pediatricians in 
our institution; a total of about 1,000 mEq. of 
bicarbonate was given in the ensuing 24 hours. 
Concomitantly, the liver becan1e increasingly 
firm by palpation. It was concluded that the cause 
of the problem was an overperfusion of the liver's 
portal system, and re-exploration was decided 
upon. On opening the abdomen, the anastomoses 
of the portacaval transposition were found to be 
patent. However, the inferior vena cava had a 
greatly increased presure, so high that there had 
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been diffuse hemorrhage in the adjacent retro-
peritoneal space. An attempt was made to reduce 
the portal venous inflow. Initially, it was hoped to 
perform a splenorenal shunt. However, the splenic 
vein was too small for this purpose, and the spleen 
was removed. Finally, a caval mesenteric shunt was 
performed. There was no apparent benefit from 
this secondary intervention, and the child died 
24 hours later. Permission for autopsy was denied. 
DISCUSSION 
There have now been 4 known attempts 
at portal venous diversion for the treatment 
of glycogen storage disease. Two of these 
patients are still alive, 1 and 5 years post-
operatively, and the third is assumed to be 
surviving after P~ years. All 3 appeared to 
have been protected from acute metabolic 
derangements, such as those of hypoglycemia 
and acidosis. In addition, the most striking 
feature in the 2 cases with the longest follow-
up was the rapid growth rate which followed 
operation. There is reason to doubt that the 
procedure caused any change in the glyco-
gen concentration of the liver and that its 
benefits must be explained on other grounds. 
The principle involved in these cases was 
to make ingested glucose more readily avail-
able to the peripheral tissues. This was ac-
complished by the portacaval anastomosis. 
The second part of the procedure in the 3 
patients subjected to portacaval transposi-
tion represented an attempt to prevent the 
development of a portal-prival syndrome, 
such as that which is observed in dogs after 
Eck fistula or in man with normal livers who 
are subjected to the same procedure. 2 , 4 
Hermann and Mercer's! experience has 
suggested that such attempts at restoration 
of portal flow may not be necessary in pa-
tients with glycogen storage disease. The out-
come of our own second case has shown 
that attempts to meet this objective may be 
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dangerous. In our patient death followed 
operation within 2 days, apparently because 
of the inability of the glycogen-laden liver to 
transmit an augmented portal venous inflow. 
SUMMARY 
Two children with glycogen storage dis-
ease were treated with portacaval transposi-
tion. The first is alive and in good health 
more than 5 years later. She underwent a 
rapid increase in growth after the operation, 
while the liver remained the same size. The 
second patient died within 2 days after the 
transposition, apparently because the portal 
system of the swollen liver was unable to 
transmit the vena caval inflow. 
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